beta 2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitation

Fecha de publicación: 19/02/2019

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

Rodriguez-Serrano, M
Monto, F
D'Ocon, P

Grupos

Grupo de Investigación Clínica y Traslacional en Cardiología

Investigador Principal

Esther Roselló Lletí

Abstract

Pulmonary regurgitation (PR) is a frequent complication after repair of congenital heart disease. Three different GRK isoforms (GRK2, GRK5, and GRK3) and two beta-adrenoceptors (beta 1-AR and beta 2-AR) are present in peripheral blood mononuclear cells (PBMC) and their expression changes as a consequence of the hemodynamic and neurohumoral alterations that occur in some cardiovascular diseases. Therefore, they could be useful as biomarkers in PR. A prospective study was conducted to describe the expression (TaqMan Gene Expression Assays) of beta-ARs and GRKs in PBMC isolated (Ficoll (R) gradient) from patients with severe PR before and after pulmonary valve replacement and establish if this expression correlates to clinical status. 23 patients with severe PR were included and compared with 22 healthy volunteers (controls). PR patients before the PVR had a significantly lower expression of beta 2-AR (513.8 +/- 261.2 mRNA copies) vs. controls (812.5 +/- 497.2 mRNA copies), so as GRK2 expression (503.4 +/- 364.9 copies vs. 858.1 +/- 380.3 mRNA copies). The expression of beta 2-AR and GRK2 significantly decreases in symptomatic and asymptomatic patients, as well as in patients under treatment with beta-blockers and non-treated patients. The expression of beta 2-AR and GRK2 in PR patients recovers the normal values after pulmonary valve replacement (754,8 +/- 77,1 and 897,8 +/- 87,4 copies, respectively). Therefore, changes in the expression of beta 2-AR and GRK2 in PBMC of PR patients, could be considered as potential biomarkers to determine clinical decisions.

Datos de la publicación

ISSN/ISSNe:: 1663-9812, 1663-9812
Tipo:: Article
Páginas:: 93-93
DOI:: 10.3389/fphar.2019.00093
Factor de Impacto:: 1,228 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Rodriguez-Serrano, M:: Hosp Mortises, Serv Cardiol, Valencia, Spain
Rueda, J:: Hosp Univ & Politecn La Fe, Serv Cardiol, Valencia, Spain
Buendia, F:: Hosp Univ & Politecn La Fe, Serv Cardiol, Valencia, Spain
Monto, F:: Univ Valencia, Fac Farm, Dept Farmacol, Valencia, Spain

Univ Valencia, Estruct Recerca Interdiscipiinar Biotecnol & Biom, Valencia, Spain
Aguero, J:: Hosp Univ & Politecn La Fe, Serv Cardiol, Valencia, Spain

Ctr Nacl Invest Cardiovasc Carlos III CNIC, Area Fisiopatol Miocardio, Madrid, Spain
Osa, A:: Hosp Univ & Politecn La Fe, Serv Cardiol, Valencia, Spain
Cano, O:: Hosp Univ & Politecn La Fe, Serv Cardiol, Valencia, Spain
Martinez-Dolz, L:: Hosp Univ & Politecn La Fe, Serv Cardiol, Valencia, Spain
D'Ocon, P:: Univ Valencia, Fac Farm, Dept Farmacol, Valencia, Spain

Univ Valencia, Estruct Recerca Interdiscipiinar Biotecnol & Biom, Valencia, Spain

Keywords

pulmonary regurgitation; pulmonary valve replacement; right ventricle; congenital heart disease; beta 2-adrenoceptor; GRK2

Campos de estudio

Proyectos asociados

RED INVESTIGACION (RECAVA)

RD06/0014/0004 . INSTITUTO DE SALUD CARLOS III; FUNDACION PARA LA INV BIOMEDICA- HOSPITAL GREGORIO MARAÑON; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006